Loading
A phase 2 trial of Ruxolitinib, Capecitabine, Regorafenib in colorectal cancer, run by Incyte Corporation, active and no longer recruiting.
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib is a phase 2 interventional study registered as NCT02955940 by Incyte Corporation, with 10 participants enrolled, started 2016-11-30 and due to reach its primary completion in 2027-09-30. Interventions recorded: Ruxolitinib, Capecitabine, Regorafenib. Conditions listed: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Ruxolitinib, Incyte, Small-molecule kinase inhibitors.
Shares Ruxolitinib, Incyte, Small-molecule kinase inhibitors.
Shares Ruxolitinib, Incyte, Small-molecule kinase inhibitors.
Shares Ruxolitinib, Incyte.
Shares Ruxolitinib, Incyte.
Shares Incyte, Colorectal cancer.